7504-49-6

Usage

Uses

Used in Cardiovascular Applications:
[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-oxobutylidene]diazenium is used as a therapeutic agent for cardiovascular diseases due to its ability to release nitric oxide, which aids in vasodilation and improves blood flow.
Used in Inflammatory Disorders:
In the treatment of inflammatory disorders, [4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-oxobutylidene]diazenium is used as an anti-inflammatory agent. The released nitric oxide can modulate the immune response and reduce inflammation.
Used in Neurodegenerative Diseases:
[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-oxobutylidene]diazenium is used as a potential therapeutic agent for neurodegenerative diseases. The nitric oxide released by [4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-oxobutylidene]diazenium can play a role in neurotransmission and may help protect neurons from degeneration.
Used in Pharmaceutical Development:
In the pharmaceutical industry, [4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-oxobutylidene]diazenium is used as a key compound for the development of novel therapeutics with nitric oxide-mediated effects. Its unique properties make it a promising candidate for creating new drugs targeting various medical conditions.

Upstream product

• 3339-73-9 3-phthalimidopropanoic acid 
• 186581-53-3 diazomethane 
• 17137-11-0 3-phthalimidopropionyl chloride 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 39739-03-2 4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-butyric acid methyl ester 
• 51132-00-4 2-(4-bromo-3-oxobutyl)isoindoline-1,3-dione 
• 89587-22-4 2-[3-(4,6-Dioxo-5-phenyl-1,3a,4,5,6,6a-hexahydro-pyrrolo[3,4-c]pyrazol-3-yl)-3-oxo-propyl]-isoindole-1,3-dione 
• 1253176-62-3 2-(3-((2R,3R)-1-(bis(4-methoxy-3,5-dimethyl-phenyl)methyl)-3-phenylaziridin-2-yl)-3-oxopropyl)-1H-indene-1,3(2H)-dione 
• 1253176-47-4 2-(3-((2S,3S)-1-(bis(4-methoxy-3,5-dimethyl-phenyl)methyl)-3-phenylaziridin-2-yl)-3-oxopropyl)-1H-indene-1,3(2H)-dione 
• 1253176-63-4 2-(3-((2R,3R)-1-(bis(4-methoxy-3,5-dimethyl-phenyl)methyl)-3-cyclohexylaziridin-2-yl)-3-oxopropyl)-1H-indene-1,3(2H)-dione 
• 1253176-48-5 2-(3-((2S,3S)-1-(bis(4-methoxy-3,5-dimethyl-phenyl)methyl)-3-cyclohexylaziridin-2-yl)-3-oxopropyl)-1H-indene-1,3(2H)-dione 
• 102442-31-9 2-(4-dimethylamino-phenylimino)-3-oxo-6-phthalimido-hexanenitrile 
• 41306-64-3 2-(5-bromo-4-oxo-pentyl)-isoindole-1,3-dione 
• 3130-75-4 4-phthalimidobutyric acid 

Relevant academic research and scientific papers

Trimethylsilyldiazomethane as a versatile stitching agent for the introduction of aziridines into functionalized organic molecules

A highly enantioselective route for the introduction of aziridines into functionalized organic molecules was developed via a tandem acylation and aziridination of TMSCHN2.

2-Arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands

The invention concerns novel 2-arylimino-2,3-dihydrothiazole derivatives of general formula (I), their preparation methods and their use as medicines, in particular for treating pathological conditions or diseases wherein one (or several) somatostatin receptors is/are involved. Said pathological conditions include in particular acromegaly, pituitary adenoma or endocrine gastroenteropanceatic tumors including the carcinoid syndrome, and gastrointestinal bleeding. In general formula (I), R1 represents in particular an alkyl, aralkyl, cyclohexyl radical optionally substituted by an amino radical or R1 represents a —C(R11)(R12)—CO—R10 radical wherein R11 represents H, R12 represents in particular H, carbocyclic or heterocyclic alkyl, cycloalkyl or aralkyl and R10 represents in particular an aminoalkylamino radical; R2 represents a carcyclic or heterocyclic aryl radical optionally substituted; R3 represents in particular COR5 or a carbocyclic or heterocyclic alkyl, adamantyl, aryl radical optionally substituted, carbocyclic or heterocyclic aralkyl optionally substituted on the aryl group; and R5 represents a radical fixed by a nitrogen atom to the group CO.

Sulfur ylides 10. Modified method for the synthesis of pyrrolizine- and indolizinediones

A modified method for the synthesis of derivatives of pyrrolizinedione and iridolizinedione was proposed. The method is based on the intramolecular cyclization of keto-stabilized sulfur ylides generated in situ from diazo ketones and Me2S in the presence of Rh2(OAc)4.

Rhodium(II)-catalyzed cyclization of amido diazo carbonyl compounds

A series of acyclic diazo ketoamides were prepared from N-benzoyl-N-alkylaminopropanoic acids and were treated with a catalytic amount of rhodium(II) acetate. The resultant carbenoids underwent facile cyclization onto the neighboring amide carbonyl oxygen atom to generate seven-membered carbonyl ylide dipoles. Subsequent collapse of the dipoles with charge dissipation produce bicyclic epoxides which undergo further reorganization to give substituted 5-hydroxydihydropyridones in good yield. Depending on the nature of the substituent groups, it was possible to trap some of the initially formed carbonyl ylide dipoles with a reactive dipolarophile such as DMAD. In other cases, cyclization of the dipole to the epoxide is much faster than bimolecular trapping. A related cyclization/rearrangement sequence occurred when diazo ketoamides derived from the cyclic pyrrolidone and piperidone ring systems were subjected to catalytic quantities of Rh(II) acetate. With these systems, exclusive O-cyclization of the amido group onto the carbenoid center occurs to generate a seven-ring carbonyl ylide dipole. Starting materials are easily prepared, and the cascade sequence proceeds in good yield and does not require special precautions. The overall procedure represents an efficient one-pot approach toward the synthesis of various indolizidine and quinolizidine ring systems.